Great looking prospect in terms of its product I would agree.
But with 17k in the bank only, they will be relying on that LaJ loan for quite some time unless another partner comes along.
This means more shares issued, more dilution and continued LaJ influence.
I have no shares, but will watch with interest.
Milesy
Ann: CaPTHymone Clinical Trial Update , page-14
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.015(3.90%) |
Mkt cap ! $672.4M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $2.603M | 7.036M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 292539 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 24998 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |